India’s Molbio Diagnostics has been awarded the prestigious Kochon Prize 2024 for its groundbreaking portable molecular diagnostic platform, a transformative innovation that has significantly advanced the fight against infectious diseases globally. The Kochon Prize, instituted by the Stop TB Partnership and funded by the Kochon Foundation
Molbio Diagnostics, a pioneering in-vitro diagnostics (IVD) unicorn with a global footprint spread across over 70 countries through its Truenat® platform, today announced the launch of a strong collaboration with Niramai Health Analytix, a Bangalore-based deep-tech startup. This partnership aims to accelerate the adoption of
CrisprBits, a biotech start-up specializing in CRISPR gene-editing technology, is excited to announce a strategic collaboration with Molbio Diagnostics, a pioneer in point of care diagnostic solutions. The intent of this collaboration is to revolutionize point of care diagnostics by the introduction of CRISPR in
Goa-based Molbio Diagnostics, which provides innovative solutions for universal access to high-quality healthcare, announced that Temasek has invested $85 million in the company. Molbio is known for its game-changing Truenat® technology – a point-of-care, portable, battery-operated Real-Time PCR platform. Hailed globally as a high-impact breakthrough
